improvement, symptoms soon relapsed and all patients progressed into chronic antibiotic-refractory pouchitis. Aft er excluding secondary courses of pouchitis using endoscopy, pelvic MRT, and stool investigation for pathogens including C. diffi cile , all patients were treated by FMT with an interval of 3-4 weeks. Pouchoscopies were performed before and within 3 months aft er the fi rst FMT, and infl ammation was scored using the composite pouchitis disease activity index (PDAI) ( 4 ) . In three patients, pouch infl ammation was additionally assessed by fecal calprotectin (FC) levels before FMT and during follow-up.
Stool samples for FMT derived from two unrelated healthy donors whose stool and blood samples were screened for human immunodefi ciency virus 1 and 2, syphilis, viral hepatitis A, B, and C, C. diffi cile , Giardia lamblia , and other enteric pathogens. Donor stools were collected on the day of FMT. A measure of 150 g of stool was homogenized with 400 ml of isotonic sodium chloride. Aft erward, the homogenate was fi ltered repeatedly through a sterile gauze pad. Th e fi nished stool slurry was divided in two portions: one was immediately transferred to the endoscopy unit and administered into the jejunum during upper gastrointestinal tract endoscopy, and the other was stored at −80 °C aft er to classical treatment in ulcerative colitis (UC) and chronic pouchitis. Very recently, Moayyedi et al. ( 1 ) reported that FMT is eff ective for inducing remission in mildto-moderate UC compared with a placebo in a randomized controlled trial. However, in a second study by Rossen et al. ( 2 ) , no positive eff ects were observed aft er FMT. In contrast to the rather moderate eff ects of FMT on the course of UC, FMT for chronic pouchitis might be a more promising approach, given the documented role of bacteria in the pathogenesis. Aft er restorative proctocolectomy and ileal pouch-anal anastomosis (IPAA), pouchitis is the most common long-term complication aff ecting up to 50% of UC patients. Th e pathogenesis of pouchitis remains incompletely elucidated; however, anaerobic bacterial overgrowth and/or dysregulation of the mucosal immune response are postulated reasons. Th e response to antibiotics of patients with pouchitis supports the concept of a causal relationship between pouch dysbiosis and infl ammation. However, a recently published study on eight patients with chronic pouchitis described no benefi cial clinical response aft er a single FMT ( 3 ).
In our study, fi ve patients received three or more cycles with metronidazole and ciprofl oxacin for at least 10 days to treat pouchitis aft er IPAA. Aft er initial 15 To the Editor: Fecal microbiota transfer (FMT) may be an alternative approach 
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Deep sequencing of the complete V1V2 regions of the 16S rRNA gene ( 6 ) was used to evaluate the taxonomic composition of the stool microbiome. Analysis on the genus level showed distinct patterns of microbial community changes aft er FMT in the three analyzed patients who had received the same stable donor microbiome ( Figure 2 ). In the responding patients 1 and 3, the stool community composition successfully changed to a structure similar to that of the donor, whereas the non responding patient 2 showed a unique pattern distinct from the microbiome of the donor. However, a third FMT that derived from a diff erent donor initiated clinical remission in that patient as well. In summary, the results of our case series suggest benefi cial eff ects of FMT for patients with chronic antibiotic-dependent pouchitis. Our positive results may have depended on repeated FMT, as remission were observed in 3 of 5 patients aft er subsequent FMT. Further, we cannot exclude "super donor"-specifi c eff ects as described by Moayyedi et al. ( 1 ) . Although FMT is currently not a standardized and established therapy, this may rapidly change. Advances to facilitate FMT, diminish the invasiveness, and make it more esthetically acceptable are underway. Th e availability of encapsulated cryopreserved, concentrated, fecal-derived bacteria that may allay many of these concerns is on the horizon ( 7, 8 ) . FMT may therefore be a promising option in chronic pouchitis and other infl ammatory diseases; however, controlled and randomized studies are necessary.
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Th e authors declare no confl ict of interest. and one patient relapsed rapidly 3 months aft er FMT. Mild transient fever and moderate CRP increase appeared only in one patient aft er FMT (patient 2). Patients were followed up for a least 3 months post FMT, and sustained response was observed in 3 out of 5 patients. Endoscopic appearance ( Figure 1 ) , PDAI, and FC levels decreased, and no further antibiotic treatment courses were necessary in these four patients.
adding glycerol to a fi nal concentration of 10% ( 5 ). For subsequent FMTs, either fresh stool samples or frozen samples of the same donor were used. Th is phase 1, open-label protocol was approved by the local institutional ethics committee.
Within 4 weeks aft er the last FMT, symptoms resolved in 4 of 5 patients ( Table 1 ) . One patient described an improvement with the reduction of bowel movements, Only selected genera are shown. Patient P1 converged toward a rather stable profi le comparable to the donor's microbiotia after FMT, and it demonstrates the best clinical response. Patient P2 did not show such changes until a third FMT that derived from a different donor (data after third FMT not available). The microbiome from patient P3 converged to a profi le more comparable to the donor's microbiome 2 weeks after the fi rst FMT. The taxonomic composition was analyzed by deep sequencing of the V1V2 variable regions of the 16S rDNA essentially, as previously described ( 6 ) .
Letters to the Editor nature publishing group placed over the wire to maintain track patency ( Figure 3 ). Four weeks aft er the cystgastrostomy, the patient underwent endoscopic necrosectomy (EN). First, the cystgastrostomy track was dilated with a 12-13.5-15 mm balloon dilator. Subsequently, the pseudocyst was entered with the upper endoscope. Necrosectomy was performed with a variety of endoscopic tools (forceps, Roth nets, and snares) to remove necrotic material until the granulation tissue was reached. Follow-up CT scan showed resolution of the collection, and the cystgastrostomy stents were removed 3 weeks later. Th e patient continued to be asymptomatic a year post intervention.
Walled-off Pancreatic Necrosis (WOPN) can occur in 1-9% of all acute pancreatitis fl uid collection seen on ultrasound. Ten days later, the patient developed fever and abdominal pain. A computed tomography (CT) scan was performed showing a left upper quadrant organized fl uid collection between the pancreas and the posterior gastric wall. Th e collection measured approximately 7.5×6×9 cm ( Figure 1 ) . Th e patient underwent percutaneous ultrasound guided drainage with the placement of an 8Fr pigtail catheter into the peripancreatic collection and was treated with antibiotics. Th e patient had recurrent hospitalizations because of persistent fever and pain, but eventually the symptoms resolved and the drain was removed.
Less than 2 weeks aft er the drain removal, the patient presented again with abdominal pain and fever. Abdominal CT showed recurrence of the fl uid collection adjacent to the pancreatic tail measuring 5×5×5 cm. Ultrasound guided aspiration of the fl uid collection showed thick green fl uid. Cultures grew Enterococcus Faecium. Th e patient was referred to the gastroenterology service for endoscopic cystgastrostomy/necrosectomy. Endoscopic ultrasound revealed a 45 mm by 50 mm peripancreatic fl uid collection ( Figure 2 ). Cystgastrostomy was performed by passing a 19-gauge needle through the stomach into the fl uid collection; the fl uid was cloudy, brown, and watery. A wire was threaded through the needle under fl uoroscopic guidance. Th e track was dilated with a 10-12 mm then 12-15 balloons dilators. Four plastic double pigtail stents (one 7Fr×4 cm and three 10Fr×1 cm) were To the Editor: A 5-year-old boy was undergoing treatment for acute lymphoblastic leukemia with cytarabine, vincristine, pegasparaginase, methotrexate, and dexamethasone. A month following the initiation of therapy, he developed acute pancreatitis, which was felt to be secondary to pegasparaginase. Th e pancreatitis was complicated by a large peripancreatic 
